Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620139 · ClinicalTrials.gov registry record
Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 17
- Enrollment target
NCT00620139: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00620139 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620139 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This pilot study seeks to evaluate the feasibility of measuring the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic target molecules in Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, this study proposes to evaluate the extent to which CRT induces the differential expression of components along two critical, and potentially interdependent, molecular pathways: the arachidonic acid and epidermal growth factor receptor (EGFR) signaling pathways.
Interventions
- BIOLOGICAL the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-03 |
| Est. Completion | 2013-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620139
The ClinicalTrials.gov registry entry for NCT00620139 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis, is the first listed.
NCT00620139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620139 about?
NCT00620139 is a clinical study titled "Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma". This pilot study seeks to evaluate the feasibility of measuring the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic target molecules in Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, this study proposes to evaluate the extent to which C...
What is the current status of trial NCT00620139?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2005-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00620139?
The interventions under investigation include: the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis, (BIOLOGICAL).
Who is sponsoring clinical trial NCT00620139?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.